Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Benjamin Zeskind"'
Autor:
Jenny Zhang, Howard Kaufman, Sarah Kolitz, Jason Kim, Yoonjeong Cha, Rebecca Kusko, Rajaraman Krishnan, Benjamin Zeskind
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/08742e93fdd9484eab94fdfc5ef8d65a
Autor:
Fadi Towfic, Jason M Funt, Kevin D Fowler, Shlomo Bakshi, Eran Blaugrund, Maxim N Artyomov, Michael R Hayden, David Ladkani, Rivka Schwartz, Benjamin Zeskind
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e83757 (2014)
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and reg
Externí odkaz:
https://doaj.org/article/d9ac4720e37d456aa3e0668f876f8ecc
Autor:
Brett Hall, Anna Travesa, Amy Yamamura, Amy Axel, Sarah Kolitz, Jason Funt, Kevin Fowler, Matthew Nord, Praveen Nair, Scott Barrett, Benjamin Zeskind, Peter King
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Peter J. King, Matthew Nord, Anna Travesa, Amy Axel, Sarah Kolitz, Jason Funt, Kevin Fowler, Biren Amin, Praveen Nair, Scott Barrett, Benjamin Zeskind, Brett Hall
Publikováno v:
Journal of Clinical Oncology. 40:e16297-e16297
e16297 Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ̃2% are G12C, a specific KRAS mutation targeted by inhibitors such as sotorasib or adagrasib
Autor:
Brett Hall, Praveen Nair, Kevin Fowler, Amy Axel, Sarah Kolitz, Jason Funt, Scott Barrett, Benjamin Zeskind, Peter J. King
Publikováno v:
Journal of Clinical Oncology. 40:e15084-e15084
e15084 Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique position in the MAPK cascade, it remains an attrac
Publikováno v:
Biochimica et biophysica acta. Reviews on cancer. 1876(1)
Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model it has created a promising environment for revolutionizing cancer diagnosis, treatment, prevention, and drug discovery.
Autor:
Jason K. Kim, Sarah Kolitz, Rebecca Kusko, Jenny Z. Zhang, Howard L. Kaufman, Benjamin Zeskind, Rajaraman Krishnan, Yoonjeong Cha, Sailaja Battula
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background COVID-19 is a global public health crisis with no effective therapeutic strategies or vaccines available. The disease is caused by the SARS-CoV-2 virus, a novel coronavirus that enters cells through the ACE2 receptor. To rapidly identify e
Autor:
Sailaja Battula, Howard L. Kaufman, Benjamin Zeskind, Yoonjeong Cha, Sarah Kolitz, Rebecca Kusko
Publikováno v:
Regular and young investigator award abstracts.
Background Uveal melanoma is a rare variant of melanoma associated with monosomy 3, present high risk for metastatic disease, and has been resistant to all therapeutic approaches. We sought to use a novel advanced big data approach to identify potent
Autor:
Sigal Melamed-Gal, Pippa Loupe, Bracha Timan, Vera Weinstein, Sarah Kolitz, Jenny Zhang, Jason Funt, Arthur Komlosh, Nurit Ashkenazi, Oren Bar-Ilan, Attila Konya, Olga Beriozkin, Daphna Laifenfeld, Tal Hasson, Benjamin Zeskind, Michael Hayden, Steffen Nock, Iris Grossman
Publikováno v:
eNeurologicalSci
Autor:
Arthur Komlosh, Kevin Wells-Knecht, Michael R. Hayden, Vera Weinstein, Adrian Gilbert, Attila Konya, Kevin D. Fowler, Revital Krispin, Sarah Kolitz, Sigal Melamed-Gal, Iris Grossman, Pippa S. Loupe, Galia Papir, Yousif Sahly, Benjamin Zeskind, Oren Bar-Ilan, Daphna Laifenfeld, Tal Hasson, Tatiana Molotsky
Publikováno v:
Annals of the New York Academy of Sciences. 1407:75-89
Copaxone (glatiramer acetate, GA), a structurally and compositionally complex polypeptide nonbiological drug, is an effective treatment for multiple sclerosis, with a well-established favorable safety profile. The short antigenic polypeptide sequence